Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 6 | Journal of Neurodevelopmental Disorders

Fig. 6

From: Acute administration of NLX-101, a Serotonin 1A receptor agonist, improves auditory temporal processing during development in a mouse model of Fragile X Syndrome

Fig. 6

No genotype difference in ITPC was found at P21, but NLX-101 treatment increased ITPC in KO mice in the auditory cortex. A-B) No significant difference in ITPC for gap-ASSR was seen between Fmr1 WT and KO mice in the auditory and frontal cortex. C-F) Treatment effect of NLX-101 was found significant with three-way ANOVA. NLX-101 significantly increased ITPC in the auditory, but not the frontal, cortex. Full statistics report is in Table 4. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars show standard deviation

Back to article page

Journal of Neurodevelopmental Disorders

ISSN: 1866-1955

Contact us